'Singing for Lung Health’ group participation after pulmonary rehabilitation completion. A feasibility study

Randomised controlled feasibility study of maintaining the benefits of pulmonary rehabilitation with harmonies and melodies via singing for lung health. The WHAM study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11056049

Enrollment

Registered

2021-09-17

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rehabilitation from all lung conditions Respiratory

Interventions

Intervention group – Home-exercise advice (standard care) + Singing for Lung Health (SLH) group participation Individuals will participate in once-weekly SLH sessions for 12 weeks and receive routine

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older 2. Received a full course of SARS-CoV-2 vaccine 3. Received an annual flu vaccine 4. Received a pneumonia vaccination 5. Clinician diagnosis of COPD, Asthma, Bronchiectasis or ILD 6. Stable respiratory health in the preceding 4 weeks without exacerbating 7. Completion of PR defined as completing at least 8 sessions. 8. Attend a baseline assessment within a month of completing PR 9. Informed consent provided by participant.

Exclusion criteria

Exclusion criteria: 1. Previous attendance at Singing for Lung Health group sessions or regularly participating in any other singing group activity. 2. Have a life-limiting co-morbidity 3. Unable to consent

Design outcomes

Primary

Measure	Time frame
Proportion of patients who complete SLH after completing PR, defined as attending at least 8 out of 12 sessions of SLH measured using case report forms	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 17/11/2025: Measured using case report forms unless otherwise noted: 1. Rates of PR completer participants commencing the trial 2. The number of eligible participants completing local PR programmes 3. The percentage of PR programmes who successfully implement the singing taster session within their PR 4. Recruitment rate per site in the RCT 5. The standard deviations of key outcome measures including the Dyspnoea-12 and Multidimensional Dyspnoea Profile in response to SLH after PR to be able to determine a sample size for a future trial (analysed following 12 weeks of intervention or control participation) 6. The feasibility of recording home practice SLH sessions in patient diaries. This will be calculated as a mean percentage recorded sessions 7. The number of patients in the control arm who continue in the trial to 24 weeks. This will be calculated as whether there is any significant difference in drop-out rates across the trial between intervention and control groups. 8. The feasibility of an economic evaluation. The aim is to develop and understand the accuracy, reliability and practicality of the data collection tools associated with resource use and quality of life data, and variability in this data. This will be analysed according to baseline data collected from the health service inventory and the questionnaire completed once again at 24 weeks. 9. The feasibility of collecting disease specific and general health related quality of life data according to completion rates of the COPD Assessment/Asthma Quality of Life Questionnaire/Kings Brief ILD questionnaire/Bronchiectasis Health Questionnaire, Voice related QOL questionnaire, EQ-5D-5L (Collected at baseline, 12 weeks and 24 weeks). 10. The perspectives of stakeholders across sites (PR leaders, singing leaders and patients), regarding experiences and the design of the Trial. These will be obtained via qualitative interviews. 11. Change in exercise capacity within and	—

Measure

Time frame

Current secondary outcome measures as of 17/11/2025: Measured using case report forms unless otherwise noted: 1. Rates of PR completer participants commencing the trial 2. The number of eligible participants completing local PR programmes 3. The percentage of PR programmes who successfully implement the singing taster session within their PR 4. Recruitment rate per site in the RCT 5. The standard deviations of key outcome measures including the Dyspnoea-12 and Multidimensional Dyspnoea Profile in response to SLH after PR to be able to determine a sample size for a future trial (analysed following 12 weeks of intervention or control participation) 6. The feasibility of recording home practice SLH sessions in patient diaries. This will be calculated as a mean percentage recorded sessions 7. The number of patients in the control arm who continue in the trial to 24 weeks. This will be calculated as whether there is any significant difference in drop-out rates across the trial between intervention and control groups. 8. The feasibility of an economic evaluation. The aim is to develop and understand the accuracy, reliability and practicality of the data collection tools associated with resource use and quality of life data, and variability in this data. This will be analysed according to baseline data collected from the health service inventory and the questionnaire completed once again at 24 weeks. 9. The feasibility of collecting disease specific and general health related quality of life data according to completion rates of the COPD Assessment/Asthma Quality of Life Questionnaire/Kings Brief ILD questionnaire/Bronchiectasis Health Questionnaire, Voice related QOL questionnaire, EQ-5D-5L (Collected at baseline, 12 weeks and 24 weeks). 10. The perspectives of stakeholders across sites (PR leaders, singing leaders and patients), regarding experiences and the design of the Trial. These will be obtained via qualitative interviews. 11. Change in exercise capacity within and

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026